SST receptor imaging

A commonly used imaging agent for SST receptor imaging is 111In or 99mTc labeled octreotide. Tumor SST receptor imaging has high sensitivity to many neuroendocrine and non-neuroendocrine tumors, and is the preferred method for preoperative localization of gastrinoma, insulinoma, and glucagonoma. SST receptor imaging is not only used for the localization diagnosis, staging and prognosis evaluation of tumors, but also has important value in the evaluation of tumor-directed surgery and octreotide treatment. Basic Information Specialist Category: Oncology Inspection Category: Radionuclide Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: It has high sensitivity to many neuroendocrine and non-neuroendocrine tumors, and is the preferred method for preoperative localization of gastrinoma, insulinoma and glucagonoma. Tips: Please check the day on an empty stomach. Normal value Receptor imaging was negative. Clinical significance Abnormal results: Tumor SST receptor imaging has high sensitivity to many neuroendocrine and non-neuroendocrine tumors, and is the preferred method for preoperative localization of gastrinoma, insulinoma, and glucagonoma. SST receptor imaging is not only used for the localization diagnosis, staging and prognosis evaluation of tumors, but also has important value in the evaluation of tumor-directed surgery and octreotide treatment. People who need to be examined: Tumor patients and tumors need to be examined during treatment. Positive results may be diseases: insulinoma, gastrinoma, neuroendocrine tumor, glucagonoma precautions Forbidden before inspection: Please check the expedition to the undergraduate room on the same day. Some patients may require a laxative to clear the intestines before the imaging test. Requirements for examination: 10 minutes before the start of the tracer injection and after the injection, the patient should be at rest and use a sedative if necessary. Blood glucose should be monitored before the tracer is injected. Inspection process Receptor imaging of radionuclide-labeled ligands such as vasoactiveintestinal peptide (VIP) or somatostatin (SST) has demonstrated its clinical utility. Moreover, these imaging methods can also help to effectively treat tumors by providing the correct in vivo features of tumor receptor expression. Not suitable for the crowd Inappropriate people: no special requirements. Adverse reactions and risks Nothing.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.